{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:03:50Z","timestamp":1765976630190,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["PANDORA FOR2886, CRC1483 EmpkinS and CRC1181"],"award-info":[{"award-number":["PANDORA FOR2886, CRC1483 EmpkinS and CRC1181"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["ERC Synergy grant 4D Nanoscope, ERC Consolidator g"],"award-info":[{"award-number":["ERC Synergy grant 4D Nanoscope, ERC Consolidator g"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"crossref","award":["MASCARA Project"],"award-info":[{"award-number":["MASCARA Project"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Baricitinib (BARI) is approved for the treatment of rheumatoid arthritis (RA) after failure of conventional synthetic and biologic disease modifying anti-rheumatic drugs (cs\/bDMARDs) in combination with methotrexate (MTX) or as monotherapy. However, real-world data are scarce regarding efficacy and drug persistence for BARI monotherapy (BARI-mono) versus its combination with MTX (BARI-combo).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate efficacy and drug persistence of BARImono compared with BARI-combo in routine clinical practice<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with RA who were switched to BARI were included in a prospective, monocentric cohort. Demographics, clinical outcomes, adverse events and medication were prospectively recorded every 3 months. Clinical efficacy was measured by DAS-28 ESR while drug persistence was measured as the time on drug. We estimated least-square mean DAS-28 scores over time using linear mixed effects models including time-group interactions. Kaplan-Meier method was used to estimate BARI survival and probability of remission over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>139 patients (98\u2009women; aged 58.4 (12.8) years; mean disease duration of 9.7 years) were included between 2017 and 2021. 46 patients received BARI-combo, 93 patients received BARI-mono. Mean DAS-28 ESR were not significantly but only numerically different between both groups at baseline and multiple timepoints over follow-up. DAS-28 ESR remission was attained at least once upto 48 weeks in 62% and 51% patients in BARI-combo versus BARI-mono group (log-rank p=0.64). Drug persistence was high (69 vs 67% at 48 weeks and 62% vs 56% at 96 weeks) and similar in BARI-combo-treated and BARI-mono-treated patients. b\/ts DMARD na\u00efve patients had lower mean DAS-28 scores over the follow-up and attained DAS-28 ESR remission earlier than patients with inadequate response to b\/ts DMARDs (p=0.11). BARI was discontinued in 11\/139 patients (7.9%) due to adverse effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In routine practice, BARI is effective as monotherapy in case of MTX intolerance with overall high drug persistence rates. No new safety signals were observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002674","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:10:54Z","timestamp":1669029054000},"page":"e002674","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study"],"prefix":"10.1136","volume":"8","author":[{"given":"Sara","family":"Bayat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Bohr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-4325","authenticated-orcid":false,"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9695-0657","authenticated-orcid":false,"given":"Johannes","family":"Knitza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-7728","authenticated-orcid":false,"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 Rheumatology and Immunology, Universit\u00e4tsklinikum Erlangen, Erlangen, Bayern, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"2025090312374152000_8.2.e002674.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"2025090312374152000_8.2.e002674.2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases. reply","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090312374152000_8.2.e002674.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090312374152000_8.2.e002674.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090312374152000_8.2.e002674.5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312374152000_8.2.e002674.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2025090312374152000_8.2.e002674.7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/acr.24007","article-title":"Efficacy and safety of Long\u2010Term Baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with Baricitinib monotherapy continuation or after switching from methotrexate monotherapy or Baricitinib plus methotrexate","volume":"72","author":"Fleischmann","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025090312374152000_8.2.e002674.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051718"},{"key":"2025090312374152000_8.2.e002674.9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys223"},{"key":"2025090312374152000_8.2.e002674.10","doi-asserted-by":"publisher","DOI":"10.1370\/afm.516"},{"key":"2025090312374152000_8.2.e002674.11","doi-asserted-by":"crossref","DOI":"10.3390\/medicines9030018","article-title":"The impact of industry funding on randomized controlled trials of biologic therapies","volume":"9","author":"Gazendam","year":"2022","journal-title":"Medicines"},{"key":"2025090312374152000_8.2.e002674.12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","article-title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study","volume":"39","author":"Guidelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312374152000_8.2.e002674.13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","article-title":"Real-World treatment patterns and clinical outcomes of Baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (the ORBIT-RA study)","volume":"9","author":"Hern\u00e1ndez-Cruz","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090312374152000_8.2.e002674.14","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data","volume":"61","author":"Barbulescu","year":"2022","journal-title":"Rheumatology"},{"key":"2025090312374152000_8.2.e002674.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181398"},{"key":"2025090312374152000_8.2.e002674.16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1756-185X.13199","article-title":"Two-Year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry","volume":"21","author":"Favalli","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025090312374152000_8.2.e002674.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2025090312374152000_8.2.e002674.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"2025090312374152000_8.2.e002674.19","first-page":"24","article-title":"Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients","volume":"43","author":"Gonz\u00e1lez-Fern\u00e1ndez","year":"2019","journal-title":"Farm Hosp"},{"key":"2025090312374152000_8.2.e002674.20","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s10067-016-3349-z","article-title":"Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability","volume":"35","author":"Iannone","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312374152000_8.2.e002674.21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/03009742.2016.1141979","article-title":"Long-Term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice","volume":"45","author":"Leon","year":"2016","journal-title":"Scand J Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:37:48Z","timestamp":1756928268000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/rmdopen-2022-002674"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002674","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}